Stock ALLO ALLOGENE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Allogene Therapeutics, Inc.

Equities

ALLO

US0197701065

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-26 EDT 		5-day change 1st Jan Change
2.89 USD +1.23% Intraday chart for Allogene Therapeutics, Inc. -16.71% -9.97%
04-26 Allogene Therapeutics Gets $15 Million Grant from California Institute for Regenerative Medicine for Cancer Drug Development MT
04-26 Allogene Therapeutics Receives Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Allogene Therapeutics Gets $15 Million Grant from California Institute for Regenerative Medicine for Cancer Drug Development
MT
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
GL
Allogene Therapeutics Receives Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
CI
Allogene Therapeutics Announces Q2 Investor Conference Participation
GL
Allogene Therapeutics, Inc.(NasdaqGS:ALLO) added to S&P Biotechnology Select Industry Index
CI
Allogene Therapeutics Files $500 Million Mixed Shelf
MT
Transcript : Allogene Therapeutics, Inc., Q4 2023 Earnings Call, Mar 14, 2024
Allogene Therapeutics Q4 Loss Narrows, Revenue Drops
MT
Allogene Therapeutics: Q4 Earnings Snapshot
AQ
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
GL
Allogene Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
GL
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
GL
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
GL
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
AQ
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
AQ
Allogene Therapeutics to Restate Financial Statements Due to Accounting Adjustments
MT
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
GL
Allogene Therapeutics, Inc. Announces Restate Financial Statements for the Years Ended December 31, 2020, 2021 and 2022 and Interim Quarters During 2022 and 2023
CI
HC Wainwright Adjusts Allogene Therapeutics Price Target to $10 From $12, Maintains Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALLO Stock
  4. News Allogene Therapeutics, Inc.